Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

ERBB3

2 articles · Resources: NCBI Gene, OncoKB

Clinical

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

Xu CR, Zhang Y, Lin G, et al.

Lancet (London, England)

The randomized phase 3 HERON-Lung01 trial evaluated the efficacy and safety of ruzaltatug rezetecan, a novel HER3-directed antibody-drug conjugate (ADC), compared with platinum-pemetrexed chemotherapy in 498 patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who progressed on prior EGFR tyrosine kinase inhibitor (TKI) therapy. At the prespecified interim analysis, ruzaltatug rezetecan significantly prolonged progression-free survival compared to chemotherapy (median 8.3 months vs 5.4 months; HR 0.47; p < 0.0001). The safety profile was manageable, with grade 3 or higher treatment-related adverse events occurring in 41% vs 39% of patients, predominantly hematological, and leading to treatment discontinuation in only 1% per arm. These findings establish ruzaltatug rezetecan as a promising post-TKI therapeutic option in advanced EGFR-mutated NSCLC.

Clinical · Molecular biology

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial

Jhaveri K, Eli LD, Hurvitz SA, et al.

Clinical cancer research

This SUMMIT basket trial study evaluated the efficacy of neratinib alone or in combination with trastuzumab in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC). Results showed confirmed objective response rates of 40% for neratinib alone and 35.3% for the combination, with median progression-free survival times of 2.89 and 6.24 months, respectively. Circulating tumor DNA (ctDNA) monitoring correlated decreases in HER2 mutation variant allele frequencies with treatment response and identified the emergence of resistance mutations. The neratinib and trastuzumab combination appears to prolong responses compared to neratinib alone, offering a novel approach for biomarker-defined metastatic TNBC.